Capnia (NASDAQ: SLNO) and NeuroMetrix (NASDAQ:NURO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Earnings & Valuation

This table compares Capnia and NeuroMetrix’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Capnia $1.27 million 16.48 -$11.12 million ($0.75) -0.59
NeuroMetrix $15.72 million 0.22 -$13.27 million ($20.01) -0.09

Capnia has higher revenue, but lower earnings than NeuroMetrix. Capnia is trading at a lower price-to-earnings ratio than NeuroMetrix, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Capnia has a beta of 6.64, suggesting that its share price is 564% more volatile than the S&P 500. Comparatively, NeuroMetrix has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Capnia and NeuroMetrix, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capnia 0 0 1 0 3.00
NeuroMetrix 0 0 2 0 3.00

Capnia presently has a consensus price target of $5.00, indicating a potential upside of 1,036.62%. NeuroMetrix has a consensus price target of $26.00, indicating a potential upside of 1,328.57%. Given NeuroMetrix’s higher probable upside, analysts plainly believe NeuroMetrix is more favorable than Capnia.

Institutional & Insider Ownership

34.4% of Capnia shares are held by institutional investors. Comparatively, 38.5% of NeuroMetrix shares are held by institutional investors. 69.8% of Capnia shares are held by company insiders. Comparatively, 4.4% of NeuroMetrix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Capnia and NeuroMetrix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Capnia -926.95% -112.32% -88.36%
NeuroMetrix -83.92% -209.56% -135.03%

Summary

Capnia beats NeuroMetrix on 7 of the 12 factors compared between the two stocks.

About Capnia

Soleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief. The Company has developed the CoSense End-Tidal Carbon Monoxide Monitor that measures ETCO for the detection of dangerous hemolysis rates. The Infant Solutions product line, including the NeoPIP Infant Resuscitator Unit and accessories, is designed for controlled and accurate resuscitation of neonates and infants in the clinical environment. Serenz Nasal Relief is a hand-held nasal irrigator that uses carbon dioxide (CO2) gas to wash the nasal passages.

About NeuroMetrix

NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.

Receive News & Ratings for Capnia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capnia Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.